The scope of this study includes what a CGM is, how it works and how a PWD wears the device. This study includes advances in the technology - both those advances being seen in the market today and advances for which CE mark or FDA approval is pending. There is a section covering the pancreas and diabetes, including the continued growth in the number of diabetics and prediabetics in the U.S. and elsewhere. It covers selected clinical trials pertaining to the evolution and proliferation of CGMs. The scope of this report includes novel CGMs and components in development. These may or may not ever see a market launch but should nonetheless be of interest to industry managers.
Also covered here are selected regulatory and reimbursement affairs. Regulatory guidelines need to keep abreast of the technological developments so that safe, effective devices may enter the market. Without sufficient, carefully crafted reimbursement or payer coverage, the devices will never get off the ground. Both favorable regulatory and reimbursement guidelines are needed if manufacturers are to continue to develop and commercialize the best equipment for managing diabetes.
Selected companies are profiled in this report. These include not only the market leaders - Dexcom, Medtronic, Abbott, Tandem, and Insulet - but also smaller companies working on promising technology.
The Report Includes:
An overview of the current state of the art for CGM for diabetes
Analyses of global market trends with data from 2018, 2019, and projections of CAGRs through 2024
Encompassing details of CGM functionalities like how they work, who can use one, and when a CGM could help to better manage the disease
Examination of the critical issues within the CGM market, including technological developments, geographic trends, market dynamics, adoption trends, and clinical trials
Evaluation of current market size, market forecast, and future of the CGM device industry
Market share analysis of the leading players of the industry and their comprehensive company profiles
The study's goals include:
Presenting the current products in the U.S., EU and elsewhere.
Looking at the technologyboth on the market and in development.
Tracing improvements that companies are engineering and where these improvements may lead within the market.
Examining how close the industry is to a device-based artificial pancreas (AP).
Exploring selected clinical trials, the conclusions are drawn from the research, and how the clinical trials affect the further development of CGM.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Executive Summary
Chapter 3 Definitions
Chapter 4 Increasing Patient Choice and Device Interoperability
Advances in the Closed-Loop Insulin Delivery System
Barriers to a Fully Automated Closed-Loop System
Tandem's Control-IQ Technology
Tidepool Loop and Interoperable Insulin Pumps
Medtronic's Next-Gen Advanced Hybrid Closed Loop System
Medtronic's European Envision Pro CGM
Biolinq's New CGM Sensor
Senseonics and Its Eversense Implantable CGM
Lilly: Connected Pens, Dexcom and Hybrid Closed-Loop System
WaveForm Cascade CGM
Timeline of Recent Device and Software Approvals
Chapter 5 Novel CGMs and Components in Development
Smartwatches and Wristbands
Traditional Wearable Sensors
Implantable CGM Sensors
Integrated Medical Sensors Inc.
Other Potential Noninvasive CGMs
Chapter 6 Technological Promises or Hype?
MIT and Noninvasive Blood Glucose Monitoring
How Raman Spectroscopy Works
The Future of Raman Spectroscopy for Measuring Blood Glucose
Optogenetics: Ready to Revolutionize Diabetes Treatment?
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.